|
|
Article: Panacea Pharmaceuticals' Series C Round Gets $7M.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Panacea Pharmaceuticals Inc. raised $7 million in a Series C round for its preclinical program focused on the enzyme human aspartyl (asparaginyl) beta-hydroxylase, or HAAH, found overexpressed on surface cells in more than 20 tumor types.
"We're focusing on liver cancer for clinical models," said Kasra Ghanbari, co-founder and board member of Gaithersburg, Md.-based Panacea, though definite decisions will not be made until later.
Whether the research will yield as much therapeutic fruit, as the company's "cure all" name suggests, is yet to be seen, but researchers have found HAAH in primary tumor tissue in the pancreas, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Panacea Pharmaceuticals, Inc. Announces Extension ...
PR Newswire;
January 8, 2003 ;
700+ words
... ... otherwise unless required by law. Contact: Panacea Pharmaceuticals, Inc. Kasra Ghanbari, Chief Operating Officer Phone 240-240 ... Kasra Ghanbari, Chief Operating Officer, Panacea Pharmaceuticals, Inc., +1-240-240-8000, or fax ...
|
|